News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Basilea Pharmaceutica (BSLN.SW) Swaps Its Isavuconazole North American Co-Promote Rights For Full Isavuconazole Rights Outside Of North America


2/28/2014 9:44:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BASEL, Switzerland, Feb. 28, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the amendment as of February 27, 2014 of the isavuconazole License, Co-Development and Co-Promotion Agreement with Astellas Pharma Inc. originally executed in 2010, providing Basilea full rights to isavuconazole in all markets outside of the U.S. and Canada in return for Basilea's right to co-promote the product in the U.S. and Canada and its right to receive payments related to co-promotion and EU milestone payments.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES